GORDON, K.; PAPP, K.; GOODERMAN, M.; THACI, D.; FOLEY, P.; MORITA, A.; KUNDU, S.; KISA, R.; NAPOLI, A.; BANERJEE, S. Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 3, p. S14, 2019. DOI: 10.25251/skin.3.supp.14. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/741. Acesso em: 4 jul. 2024.